INTERPRETATION OF CHANGES IN QUANTITATIVE RATIO OF NEUROTROPIC AUTOANTIBODIES IN PATIENTS WITH COVID-19
Keywords:
COVID-19, nervous system, neurotropic autoantibodies, early diagnosisAbstract
COVID-19 is a new disease in the history of mankind, the pathogenesis of the development of clinical symptoms, the early and late complications of which are not well understood. Careful observation of patients with COVID-19 has shown that the symptoms of damage to the nervous system in this disease can be varied, however, very little is known about the long-term consequences of COVID-19. Despite a significant variety of methods for studying the nervous system, the effectiveness of most of them remains low in terms of detecting the earliest preclinical changes. It is appropriate to pose the question, is there a method that can indicate with great accuracy that the pathological process has started and there is a tendency for the development of a certain disease even before the appearance of changes in the indications of the traditionally used methods of early diagnosis of this disease? When, under the influence of various etiological factors, the process of cell destruction is accelerated, the immune system begins to produce more autoantibodies so that the clearance process proceeds at an appropriate rate. This is a very important point, since it is the increase in the levels of specific autoantibodies that is the very early and sensitive marker indicating the start of the pathological process long before the appearance of biochemical preclinical shifts. The ELI-Neuro-Test method of immunochemical analysis makes it possible to comprehensively assess the state of neurotransmitter systems and, long before the appearance of neurological or psychiatric symptoms, with a high probability of predicting diseases of the central nervous system, in particular those associated with COVID-19. Using this method, an individual profile of serum immunoreactivity is analyzed, depending on changes in the relative content of IgG autoantibodies directed to 12 autogens of the nervous system. The significant number of people who have had COVID-19 among the population of our country, the neurotropism of the coronavirus and the possibility of developing not only early, but also late complications from the nervous system is a prerequisite for a deeper and more comprehensive study of all the most important aspects of COVID-19 associated lesions of the central nervous system.
References
Полетаев А.Б. Физиологическая иммунология (естественные аутоантитела и проблемы наномедицины) (2010).
Полетаев А.Б. Фундаментальные проблемы клинической патофизиологии (2018).
Зайратьянц О.В., Самсонова М.В., Черняев А.Л., Мишнев О.Д., Михалёва Л.М., Крупнов Н.М., Калинин Д.В.. Патологическая анатомия COVID-19: опыт 2000 аутопсий (2020).
Сайко Ю.В. Применение Актовегина при неврологических нарушениях, ассоциированных с COVID-19 (2020).
Alejandro Romero, Eva Ramos, Francisco López-Muñoz, Emilio Gil-Martín, Germaine Escames, Russel J. Reiter. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin? (2020).
Attademo L, Bernardini F. Are dopamine and serotonin involved in COVID-19 pathophysiology? (2020).
Ícaro Raony, Camila Saggioro de Figueiredo, Pablo Pandolfo, Elizabeth Giestal-de-Araujo, Priscilla Oliveira-Silva Bomfim, Wilson Savino. Psycho-Neuroendocrine-Immune Interactions in COVID-19: Potential Impacts on Mental Health (2020).
Dr Sanil Rege. COVID-19 and the Brain – Pathogenesis and Neuropsychiatric Manifestations of SARS-CoV-2 CNS Involvement (2020).
Arehally M. Mahalakshmi, Bipul Ray, Sunanda Tuladhar, Abid Bhat, Shasthara Paneyala, Duraisamy Patteswari , Meena Kishore Sakharkar, Hamdan, David M. Ojcius, Srinivasa Rao Bolla, Musthafa Mohamed Essa, Saravana Babu Chidambaram, M. Walid Qoronfleh. Does COVID-19 contribute to development of neurological disease? (2020).
Debanjan Banerjee and Biju Viswanath. Neuropsychiatric manifestations of COVID-19 and possible pathogenic mechanisms: Insights from other coronaviruses (2020).
Maura Boldrini, Peter D. Canoll, Robyn S. Klein How COVID-19 Affects the Brain (2021).
Luca Steardo and Alexei Verkhratsky. Psychiatric face of COVID-19 (2020).
Russell L. Blaylock. Excitotoxicity (Immunoexcitotoxicity) as a Critical Component of the Cytokine Storm Reaction in Pulmonary Viral Infections, Including SARS-Cov-2 (2021).
Andrew H. Miller, Ebrahim Haroon, Charles L. Raison, Jennifer C. Felger. Cytokine Targets in the Brain: Impact on Neurotransmitters and Neurocircuits (2013).
Рахимбаева Гульнора Саттаровна, Шодиев Улуғбек Дониёр ўғли. Постковид цeрeбро-астeник синдром: диагностик ёндашувларни оптималлаштириш, долзарб жихатлари // Журнал неврологии и нейрохирургических исследований №2.2021. 6-10 бет.
Ronald S. Duman, Gerard Sanacora, and John H. Krystal. GABA and glutamate neurotransmitter deficits and reversal by novel treatments (2019).
Yakubova M.M., Khalimova H.M., Parpieva Yu.R. Clinical and neurological aspects of multiple sclerosis during infection with covid-19 in uzbekistan. Central asian journal of medical and natural sciences, Volume: 02 Issue: 03 | May-June 2021 ISSN: 2660-4159, Р. 186-190
Yakubova Markhamat Mirakbarovna, Fayzieva Munis Dilshod qizi. Some aspects of ethiopathogenesis of neurological manifestations in coronavirus infection and study of the expression and prevalence of smell and taste impairments in patients with SARS-COV-2. Uzbek Medical Journal. – Volume 2, Issue 4 – Tashkent, 2021. Р. 55-61.
Jide Tian, Blake Milddleton, Daniel L. Kaufman. GABA administration prevents severe illness and death following coronavirus infection in mice (2020).
Svetlana Soković Bajić, Jelena Đokić, Miroslav Dinić, Sergej Tomić, Nikola Popović, Emilija Brdarić, Nataša Golić, Maja Tolinački. GABA potentiate the immunoregulatory effects of Lactobacillus brevis BGZLS10-17 via ATG5-dependent autophagy in vitro (2020).
Даминова М.Н., Абдуллаева О.И., Даминова Х.М.COVID-ассоциированный диарейнный синдром. Самаркандский ГосМИ,75 международная научно практическая конференция. 2021.С.548
Ходжаева Д.Т., Хайдарова Д.К., Хайдарова Н.К. Рекомендации по снижению депрессивных и тревожных расстройств в условиях карантина по коронавирусной инфекции. Услубий – тавсиянома. Бухоро-2020.
Mary EW Collier, Shaowei Zhang, Flaviano Giorgini. Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition? (2020).
Пизова Н.В., Пизов А.В. Депрессия и посттравматическое стрессовое расстройство при новой коронавирусной инфекции (2020).
Maria Di Bari, Giovanni Di Pinto, Marcella Reale, Guadalupe Mengod, Ada Maria Tata. Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis (2017).
Хайдарова Дилдора Кадировна. Характеристика неврологических симптомов при клиническом появлении covid-19. Журнал неврологии и нейрохирургических исследований. Международная конференция Актуальные вопросы неврологии. 2021 С. 52-56.
Ходжаева Д.Т., Хайдарова Д.К., Рахматова Д.И. Рекомендация и алгоритм ведения больных энцефалитом при Covid -19. Услубий – тавсиянома. Бухоро-2020
Туйчиев Л.Н., Рахимбаева Г.С., Газиева Ш.Р., Атаниязов М.К. Новая коронавирусная ин¬фекция и постковидные неврологиче¬ские последствия заболевания // Вестник ТМА № 2, 2021. 45-50 стр.
